Welcome to BioSeeker Group!

Triple Analysis: Leukemia, Melanoma and Angiogenesis

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4032
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Leukemia, Melanoma and Angiogenesis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Angiogenesis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Angiogenesis.

    To find out more about Triple Analysis: Leukemia, Melanoma and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Angiogenesis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Leukemia
The leukemia report part comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 investigators, from Ceased to Marketed. This part extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and and eight subindications of leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Part II: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part III: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Leukemia
5.1 The Scope of this Report 29
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment (204 Drug Targets) 33-443
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development (193 Drug Target Strategies and 313 Leukemia Drugs) 444-727
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy (8 Compound Strategies) 679-728
9 Selecting Subindication for Leukemia Drugs (8 Subindications of Leukemia) 729-762
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator (186 Companies) 763-1,129
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140
Figures: Includes 6 Figures
Tables: Includes 253 Tables
Total Number of Pages: 1,147

Part II: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part III: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

This Report Includes the Following Companies:
3M Pharmaceuticals
3SBio
4SC
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
Access
Actelion
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Alexion
Alfa Wassermann
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
AngioChem
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Aphios
ApopLogic Pharmaceuticals
Apotex
Arana Therapeutics
Arca biopharma
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
Bayer
Bio-Medisinsk Innovasjon
Bio-Path Holdings
BioAlliance Pharma
BioAxone
Biocad
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Biokine Therapeutics
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
Bioton
BioVex
Boehringer Ingelheim
Bolder BioTechnology
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celtic Pharma
Cephalon
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CSL
Cue Biotech
Curacyte
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytochroma
Cytokinetics
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DiaMedica
DNAVEC
Dong-A
Dyax
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Five Prime Therapeutics
Flamel Technologies
GammaCan
Gemin X Biotechnologies
Genencor
Genentech
Genmab
Genta
GenVec
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Gradalis
Green Cross
Hanmi
Hayashibara
Heber Biotec
Hemispherx Biopharma
Hoffmann-La Roche
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
Immunovaccine
ImmuPharma
Incyte Corporation
InDex Pharmaceuticals
Inex
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
Italfarmaco
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
KAI Pharmaceuticals
KaloBios
Kalypsys
Kanisa
Karus Therapeutics
Karyon-CTT
Kiadis
Kinex
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lipotek
Lorus Therapeutics
Mannkind
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
Medisyn Technologies
Memgen
Merck & Co
Merck KGaA
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Morvus Technology
Nereus Pharmaceuticals
Nerviano Medical Sciences
NewSouth Innovations
NIH
Nippon Shinyaku
Non-industrial source
Novartis
Novelix
Novogen
Noxxon
Oasmia
Oncalis
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
OSI Pharmaceuticals
Otsuka
Oxford BioMedica
OXiGENE
Pacific Biotech
Patrys
PBL Therapeutics
Pepscan Therapeutics
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaMar
Pharminox
Philogen
PhiloGene
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
Progen
ProMetic Life Sciences
Protein Sciences
Protgen
PTC Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
Rexahn
Rigel
Sangamo BioSciences
Sanofi
Sanofi-Aventis
Santaris Pharma
Santhera Pharmaceuticals
Sareum
SBI Biotech
SBIO
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shionogi
Shire
Sidus
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Southern Research Institute
Spear Therapeutics
Spirogen
SRI International
Stainwei Biotech
Stemline Therapeutics
Sunesis
SuperGen
Swedish Orphan Biovitrum
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
SynDevRx
Synta Pharmaceuticals
Syntrix
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
TargeGen
Targepeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
to-BBB
Tolerx
ToolGen
TopoTarget
Tracon Pharmaceuticals
Transgene
Trion Pharma
UCB
Valeant
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
VioQuest Pharmaceuticals
WntResearch
XBiotech
Xencor
Xerion
Yamasa Corporation
York Pharma
Zenyaku Kogyo
A Shortlist of Drugs Included are:
A6
ABT-510
AEB071
aflibercept
agatolimod
aldesleukin
alemtuzumab
ALT-801
AMG-386
amonafide malate
amsacrine
Angiozyme
apatinib
APO-866
ARQ-197
ARRY-438162
astuprotimut-r
atrasentan
Auto TAG vaccine
axitinib
barasertib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
bisantrene
BMS-663513
BMS-690514
BMS-936558
bortezomib
bosutinib
brivanib alaninate
Buparlisib
Cabozantinib
CB-10-01
cediranib
cilengitide
cladribine
clofarabine
cositecan
CSF-GM
CT-011
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
denenicokin
denileukin diftitox
DI-17E6
dinaciclib
dovitinib lactate
E-7820
E7449
elacytarabine
EMD-273063
endostatin
ENMD-2076
enocitabine
entinostat
enzastaurin hydrochloride
epirubicin
everolimus
Exherin
foretinib
fosbretabulin tromethamine
fresolimumab
ganetespib
ganitumab
gefitinib
gemtuzumab ozogamicin
glembatumumab vedotin
GliaAtak
golvatinib
GSK-1120212
GSK-2118436
GT-111
GV-1001
GVAX
HBP-347
Hi-8 MEL
histamine dihydrochloride
icrucumab
idarubicin
imatinib mesilate
INCB-24360
interferon
interferon (alpha-N1)
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (gamma)
interferon alpha-2b
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
IPP-204106
ispinesib mesylate
JI-101
JX-594
kahalalide F
L19-IL2
Lambrolizumab
LEE-011
lenvatinib
lestaurtinib
leukemia vaccine
LGX818
linifanib
LipoVIL12
lumiliximab
LY-2275796
MDX-1379
MetXia
MGCD-265
MGN-1601
midostaurin
mitoxantrone
MKC-1106-MT
MORAb-004
motesanib diphosphate
muparfostat (IV)
NGR-TNF
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
OncoVAX
OTS-102
P276-00
paclitaxel
PancAtak
pazopanib hydrochloride
PCI-27483
pegdinetanib
peginterferon alfa-2b
pentostatin
perifosine
PF-4856884
pimasertib
plitidepsin
poly-ICLC
ponatinib
ProstAtak
PTC-299
RAF-265
ramucirumab
razoxane
regorafenib
retaspimycin
rhIFN-alpha
ridaforolimus
rintatolimod
rituximab
sagopilone
sargramostim
SCIB-1
selumetinib
sirolimus
sobuzoxane
sorafenib tosylate
SU-6668
sunitinib malate
talactoferrin alfa
talminogene laherparepvec
tamibarotene
TAS-102
tasquinimod
TB-403
telatinib
Tenarad
teniposide
tesetaxel
thalidomide
thymalfasin
tipifarnib
tivozanib
trabedersen
TRC-105
tremelimumab
vandetanib
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
vosaroxin
XL-184
XL-647
YM-155
zanolimumab
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Leukemia, Melanoma and Angiogenesis.
    To find out more about Triple Analysis: Leukemia, Melanoma and Angiogenesis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Leukemia, Melanoma and Angiogenesis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Leukemia, Pancreatic Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Leukemia and Pancreatic Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Triple Analysis: Melanoma, Prostate Cancer and Apoptosis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Cancer Vaccines and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Leukemia), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Learn More


Head and Neck Cancer Drug Pipeline Update
BioSeeker Group have identified 214 companies plus partners who are today developing 236 drugs targeting head and neck cancer in development. across 222 different targets. In addition, there are 2 suspended drugs and another 59 drugs where development has been ceased. Learn More